Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

ZIKAVAX

Financiado

Cerrado

Fast track development of a Zika vaccine based on measles vector

Zika virus is an emerging mosquito-borne flavivirus. Although already isolated in 1947, to date there are no specific treatments nor any vaccines available against Zika virus disease, making it a truly neglected infectious disease... ver más

31/12/2020

EUROPEAN VACCINE I...

5M€

Presupuesto del proyecto: 5M€

Líder del proyecto

EUROPEAN VACCINE INITIATIVE EWIV No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 4 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2020-12-31

SC1-PM-06-2016: Vaccine development for malaria and...

I+D

Cerrada hace 8 años

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

4 Participantes

EUROPEAN VACCINE INITIATIVE

673.97K€ | Lider

CEA

489.02K€ | Participante

489.77K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

RYC2018-025379-I Understanding molecular mechanisms underlying Zika virus ass... 309K€ Cerrado

ZikaPLAN Zika Preparedness Latin American Network 13M€ Cerrado

NOVIRUSES2BRAIN One size fits all unique drug to eradicate multiple vira... 4M€ Cerrado

PID2019-110157RA-I00 ESTUDIO DE LOS MECANISMOS MOLECULARES CAUSANTES DE LA NEUROP... 143K€ Cerrado

ZIKAlliance A global alliance for Zika virus control and prevention 16M€ Cerrado

FLAVIVACCINE Development and characterization of a pan-flavivirus vaccine... 8M€ Cerrado

Duración del proyecto: 48 meses Fecha Inicio: 2016-12-02
Fecha Fin: 2020-12-31

Líder del proyecto

EUROPEAN VACCINE INITIATIVE EWIV No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 5M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Zika virus is an emerging mosquito-borne flavivirus. Although already isolated in 1947, to date there are no specific treatments nor any vaccines available against Zika virus disease, making it a truly neglected infectious disease. The recent rapid spread of the Zika virus in previously unaffected regions has provided strong epidemiological evidence that infection with this virus might be associated with neurological complications in adults and with an increase in severe congenital brain malformations of new-borns. Consequently, the World Health Organization has declared the recent outbreak of the Zika virus a public health emergency. The ZIKAVAX proposal has the objective to address this urgent public health issue by promoting the rapid development of a safe, effective, and affordable preventive vaccine against Zika virus infection. To achieve this goal, ZIKAVAX will use a delivery platform technology based on a measles vaccine vector with demonstrated proof of principle in humans and a preclinical track record of rapid adaptability and effectiveness for a variety of pathogens. The manufacturing process for these measles vector-based vaccines has been developed to give high yield and purity using standard equipment. In ZIKAVAX, following antigen selection and expression, immunisation studies will be conducted with the Zika vaccine candidate in mice and in a challenge model in non-human primates that will developed by the consortium. The ultimate goal of ZIKAVAX is the demonstration of safety and immunogenicity of a recombinant measles-Zika vaccine candidate in adult volunteers in a phase Ia clinical trial. ZIKAVAX is driven by a strongly committed and effective consortium of four leading European organisations highly experienced in vaccine research and development. Its partners include the European Vaccine Initiative, Institut Pasteur, Themis Bioscience GmbH and the Institute of Emerging Diseases and Innovative Therapies from the Commissariat à l’Energie Atomique.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores